Clinical Trials
18 trialsNCT02321501 2026-05-20
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03611738 2026-05-15
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT02559778 2026-04-28
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT02513667 2023-02-03
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT03087448 2022-12-27
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
University of California, San Francisco
Phase 1 Terminated
NCT02227940 2022-07-25
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT02605746 2020-12-11
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated
NCT02729961 2019-10-10
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Phase 1/2 Withdrawn
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01964157 2019-01-11
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Yonsei University
Phase 2 Unknown
NCT03399487 2019-01-11
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Yonsei University
Phase 2 Unknown
NCT02374489 2018-04-05
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
National Health Research Institutes, Taiwan
Phase 2 Terminated
NCT02343679 2017-02-01
Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Duke University
Phase 2 Withdrawn